All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2020-02-01T12:42:42.000Z

What new technologies are available in the field of CAR T manufacturing?

By Alia Mohamed, Bruce Levine
Feb 1, 2020
Share:

Bookmark this article

The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 2nd European CAR T Cell Meeting in Sitges, ES. In this video, Bruce Levine from the University of Pennsylvania, Philadelphia, US, discusses what new technologies are available in the field of CAR T manufacturing.

Bruce Levine talks about novel technologies in CAR T cell manufacturing that will increase the effectiveness of CAR T such as the incorporation of biomarkers as a prognostic factor for response. In addition to this, he explains strategies such as shorting the process of CAR T manufacturing to reduce overall costs.

What new technologies are available in the field of CAR T manufacturing?

More about...
CAR therapyCAR-T 2020CAR-T Meetings

Your opinion matters

As a result of this content, I commit to reviewing the CARTITUDE clinical program to guide my understanding of cilta-cel in clinical practice.
27 votes - 7 days left ...

Related articles

Add bookmark

ASH 2019 | Practice-changing abstracts in multiple myeloma

The Multiple Myeloma Hub has developed a downloadable resource, which provides an update on the practice-changing abstracts in multiple myeloma from ASH 2019 in preparation for ASH 2020.

Nov 25, 2020
Add bookmark

ASH 2019 | Practice-changing abstracts in multiple myeloma

The Multiple Myeloma Hub has developed a downloadable resource, which provides an update on the practice-changing abstracts in multiple...

Nov 25, 2020
Add bookmark

What advances in CAR T for multiple myeloma have occurred since last year's meeting?

Hermann Einsele discusses the new developments made in CAR T cell programs for patients with multiple myeloma.

Jan 31, 2020
Add bookmark

What advances in CAR T for multiple myeloma have occurred since last year's meeting?

Hermann Einsele discusses the new developments made in CAR T cell programs for patients with multiple myeloma.

Jan 31, 2020

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox